Bioverge

Bioverge

The Bioverge mission is to accelerate the development of solutions for intractable problems in healthcare. We accomplish this by democratizing the access, tools, and resources necessary to invest in and advance the most innovative emerging companies in the space.

The Bioverge platform is healthcare-focused and enables everyone, from family offices to investment advisors to accredited and non-accredited individuals, to invest in highly vetted healthcare startups at the cutting edge of innovation, and actively support each along their journey to transform healthcare.

Min investment
$99
Goal
$10K-$1M
Days Left
-
Location
San Francisco, CA

CrowdLustro Research Report

Security Type
Common Stock
Common stock is a security that represents ownership in a corporation.
Industry
Tech
Filed
April 28, 2021
Expires
May 07, 2021
Valuation
$10M
Valuation Cap
$10M

Use of Proceeds

General & administrative-$428,043, 40.0%

 Product development-$321,032, 30.0%

 Sales & marketing-$268,494, 25.1%

 Intermediary fees-$52,430, 4.9%

 

Management

Neil J. Littman, M.S., Founder, CEO & Managing Director
Executive Leadership Team at $3B venture philanthropy organization. Formerly Vice President of Business Development at Notable Labs. Advisor on investment banking transactions totaling $1B+.

Rick Gibb, Founder, COO & Managing Director
Investment professional at Stanford’s $450M healthcare venture capital fund. Maintained portfolio of 300+ healthcare inventions at Stanford.

Research Reports

No reports have been submitted

Become a Reporter

Key Deal Facts

Platform: Successfully closed 32 deals across 21 portfolio companies. Closed 2 multi-company “Access Funds”186% year-over-year revenue growth in 2020
Successfully closed 32 deals across 21 portfolio companies.
Closed 2 multi-company “Access Funds”
186% year-over-year revenue growth in 2020.
Portfolio:68% year-over-year growth in assets under management in 202028% unrealized gross IRR100% of portfolio companies are still operating3 portfolio companies valued at $100M+1 company exit (Blue Mesa Health acquired by Virgin Pulse)
68% year-over-year growth in assets under management in 2020
28% unrealized gross IRR
100% of portfolio companies are still operating
3 portfolio companies valued at $100M+
1 company exit (Blue Mesa Health acquired by Virgin Pulse)

0 Comments